Supernus Pharmaceuticals (SUPN) Stock Price, Quote, News & History | Benzinga

Supernus Pharmaceuticals Inc (SUPN) Stock Price, Quote, News & History

SUPNNASDAQ

Trade with Public

Trade with Public

$44.93

-0.43-0.95%

Last update: Aug 26, 1:55 PM

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Stock Report

Key Statistics

Open

$45.11

Close

-

Volume / Avg.

284.37K / 847.67K

Day Range

$44.50 - $45.43

52 Wk Range

42.45 - 59.68

Market Cap

$2.51B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

42

Short Interest

11.24%

Days to Cover

2.8

Recent Supernus Pharmaceuticals, Inc. News

Top 3 Health Care Stocks You'll Regret Missing This Quarter

The most oversold health care stocks present a buying opportunity. RSI indicator compares stock strength on up and down days, indicating short-term performance. Here's the latest list of oversold players in this sector.

Avi Kapoor

Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Revenue

Supernus and Indivior agree to merge in an all-stock deal, targeting $2.2 billion in revenue and $125 million in synergies.

Vandana Singh

Crowdstrike To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday

Avi Kapoor

Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk

The U.S. pharmaceutical industry is at the center of a policy maelstrom.

Chandrima Sanyal

These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

19.91M

Investing Cash Flow (TTM)

-14.73M

Financing Cash Flow (TTM)

31.51M

Free Cash Flow (TTM)

18.79M

Capital Expenditure (TTM)

-1.12M

Net Change in Cash (TTM)

36.69M

Analyst Trends and Forecast

1

Jul

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$2.31B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

3.14

PB Ratio (TTM)

2.56

Earnings Yield % (TTM)

-4.23%

Earnings Yield % (FWD)

-

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

138.62

Book Value / Share

$17.73

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$179.95M

Debt to Equity

0.04

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$45.11

Close

-

Volume / Avg.

284.37K / 847.67K

Day Range

$44.50 - $45.43

52 Wk Range

42.45 - 59.68

Market Cap

$2.51B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

42

Short Interest

11.24%

Days to Cover

2.8

About

Sector

Health Care

Industry

Pharmaceuticals

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse ...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Supernus Pharmaceuticals (SUPN) stock?

A

You can purchase shares of Supernus Pharmaceuticals (NASDAQ:SUPN) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Supernus Pharmaceuticals (SUPN) competitors?

A

Other companies in Supernus Pharmaceuticals’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).

Q

What is the forecast, or price target, for Supernus Pharmaceuticals (SUPN) stock?

A

Supernus Pharmaceuticals has a consensus price target of $62.40.

Q

What is the current price for Supernus Pharmaceuticals (SUPN)?

A

The stock price for Supernus Pharmaceuticals (NASDAQ: SUPN) is $44.93 last updated August 26, 2026 at 1:55 PM EDT.

Q

Does Supernus Pharmaceuticals (SUPN) pay a dividend?

A

There are no upcoming dividends for Supernus Pharmaceuticals.

Q

When is Supernus Pharmaceuticals (NASDAQ:SUPN) reporting earnings?

A

Supernus Pharmaceuticals does not have any upcoming earnings scheduled.

Q

Is Supernus Pharmaceuticals (SUPN) going to split?

A

There is no upcoming split for Supernus Pharmaceuticals.

Q

What sector and industry does Supernus Pharmaceuticals (SUPN) operate in?

A

Supernus Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.